VBI touts positive preclinical COVID-19 vaccine data

By The Science Advisory Board staff writers

Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle (eVLP) technology from VBI Vaccines (VBI).

Candidate VBI-2902 expressed a modified,‌ ‌prefusion‌ ‌form‌ ‌of‌ ‌the‌ ‌SARS-CoV-2‌ ‌spike‌ ‌protein‌ that ‌elicited‌ ‌a‌ ‌highly‌ ‌potent‌ ‌and‌ ‌focused‌ ‌neutralizing‌ ‌antibody‌ ‌response ‌and‌ ‌conferred‌ a ‌protective‌ ‌benefit‌ ‌in‌ ‌Syrian‌ ‌golden‌ ‌hamsters‌ that had ‌COVID-19. This was ‌assessed‌ ‌in‌ ‌terms‌ ‌of‌ ‌clinical‌ ‌disease‌, such as loss‌ ‌of‌ ‌body‌ ‌weight and‌ ‌lung‌ ‌inflammation. Also, the ‌vaccine‌ ‌candidate‌ ‌showed potential to be highly effective after a single dose, according to the data.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?